neuropsychiatric treatment

Cybin Inc. (AMEX:CYBN) has launched its Phase 3 pivotal program called PARADIGM, which is aimed at testing the efficacy of its lead candidate, CYB003, for treating Major Depressive Disorder (MDD) in a move that comes after three years of development. "Just three years after filing an...

Enveric Biosciences Inc (NASDAQ:ENVB), a biotechnology company specializing in neuroplastogen therapeutics for mental health conditions, has entered into a licensing agreement with MycoMedica Life Sciences. Enveric will out-license its EVM201 program, including the drug candidate EB-002 (formerly...